Clinical Guides
Hepatitis B: Testing, Care and Prevention
Hepatitis B requires laboratory confirmation, stage-aware long-term care, prevention of transmission and dependable linkage to Indian viral-hepatitis services.
MedNext Academy | 12 min read
Hepatitis B: Testing, Care and Prevention
Hepatitis B requires laboratory confirmation, stage-aware long-term care, prevention of transmission and dependable linkage to Indian viral-hepatitis services.
Summary
Hepatitis B virus (HBV) infection can be acute or chronic. Acute infection is often asymptomatic, but may cause fatigue, nausea, abdominal discomfort, dark urine, jaundice and, rarely, acute liver failure. Chronic infection may remain silent for years while fibrosis, cirrhosis and hepatocellular carcinoma develop. Clinical appearance alone cannot distinguish HBV from other causes of hepatitis; serology and, when indicated, HBV DNA, liver tests and fibrosis assessment are essential.
Transmission occurs most efficiently through perinatal exposure, early childhood exposure, sexual contact, blood exposure, unsafe injections, shared injecting equipment and unsterile sharp instruments. It is not spread by sharing food, casual contact, hugging or ordinary classroom contact. Vaccination is the principal prevention intervention, including timely infant vaccination; safer injections, screened blood and harm-reduction services are complementary measures.
Acute HBV normally receives supportive care. Chronic HBV is not automatically treated with a short course: WHO describes tenofovir or entecavir as oral treatment options, and many people who start treatment require long-term therapy. Eligibility depends on the current guideline, liver disease stage, viral replication, comorbidity and service context. This guide is educational and has been reviewed by the MedNext Clinical Team; it does not replace a local specialist decision, medicine label or the Indian National Viral Hepatitis Control Programme pathway. [WHO HBV Fact Sheet, Overview, Diagnosis and Treatment]
How Common Is It?
HBV remains a major global cause of cirrhosis and liver cancer. WHO estimates that 240 million people were living with chronic HBV infection in 2024, with about 0.9 million new infections and 1.1 million deaths, largely from cirrhosis and hepatocellular carcinoma. These are modelled global estimates, not an individual prognosis or a current India prevalence figure. Risk is shaped by age at infection, coinfections, alcohol and metabolic liver disease, treatment access, and duration of infection.
The probability of chronic infection is strongly related to the age at acquisition: perinatal and early-childhood infection carries a substantially greater chronicity risk than adult-acquired infection. This is why birth-dose and childhood immunisation matter even where acute clinical hepatitis is uncommon. People with chronic infection may feel well until late disease, so symptom-based detection misses many cases. WHO reports that only 27% of people estimated to be living with HBV knew their status in 2024.
India has a heterogeneous burden across states and populations. Do not use one historic prevalence survey to describe every region or assume that an individual is infected because they belong to a community. The NVHCP operational guidance instead emphasises testing high-risk groups, antenatal prevention, blood safety, district diagnostic capacity and treatment-centre linkage. Coverage, turnaround times and medicine availability vary in practice. [WHO HBV Fact Sheet, Key facts and Diagnosis; NVHCP Operational Guidelines, Prevention and Diagnosis sections]
Risk Factors
Take a non-judgemental exposure history. Ask about maternal HBV status, household and sexual contact with a person with HBV, childhood exposure, prior transfusion or dialysis, injection or needle-sharing exposure, healthcare or laboratory work, tattoos or piercing with uncertain sterilisation, imprisonment or other closed settings, and residence or birth in a higher-prevalence area. Ask about previous vaccination and documented anti-HBs response only when clinically relevant; self-reported vaccination does not establish present infection or immunity.
Assess clinical risks for progressive liver disease: alcohol, obesity and diabetes, HIV, hepatitis C or D risk, immunosuppressive therapy, chemotherapy, transplant evaluation and family history of cirrhosis or liver cancer. HBsAg-positive people should be assessed for hepatitis D under current WHO guidance, because coinfection can change urgency and management. Pregnancy is a key prevention opportunity, not a reason to stigmatise the parent. Test and counsel partners and household contacts according to local services.
Healthcare workers have both exposure and patient-safety considerations. Follow occupational-health policies after a needlestick; do not wait for symptoms. People who inject drugs need vaccination, sterile equipment and integrated care, not exclusion from treatment. India-specific decisions on who is offered testing, free services and referral must follow current NVHCP and state pathways, which may differ from WHO population-testing thresholds. [WHO HBV 2024 Guideline, Chapters 4-5 and 9; WHO Consolidated Handbook 2026, prevention and testing chapters]
Diagnosis
History
Establish symptoms, timing, pregnancy, immunisation, exposures, alcohol and medicines, including traditional or herbal products. Ask about jaundice, dark urine, pale stools, pruritus, nausea, fever, fatigue, right-upper-quadrant pain, bleeding, confusion, ascites and weight loss. Enquire about sexual and household contacts, injecting exposure, transfusions, dialysis, occupational incidents and previous hepatitis tests. Review immunosuppression and chemotherapy plans because HBV reactivation prevention may be urgent.
Examination
Assess stability and encephalopathy first. Look for jaundice, dehydration, hepatomegaly, splenomegaly, ascites, peripheral oedema, bruising, asterixis, altered mental status and stigmata of chronic liver disease. Measure weight, blood pressure and metabolic risk. A normal examination does not exclude chronic HBV. Acute confusion, coagulopathy, rapidly deepening jaundice or vomiting with poor intake requires emergency assessment for acute liver failure.
Investigations
Start with HBsAg using an appropriate quality-assured assay and interpret it with total anti-HBc, anti-HBs, HBeAg/anti-HBe and HBV DNA as indicated; patterns distinguish infection, immunity and exposure but need trained interpretation. Obtain ALT/AST, bilirubin, albumin, INR, full blood count, creatinine/eGFR and pregnancy test where relevant. Assess fibrosis with validated non-invasive testing or elastography where available; ultrasound supports structural assessment but does not stage all fibrosis. Test for HIV, HCV and HDV in line with current guidance. WHO promotes point-of-care and reflex HBV DNA approaches where feasible, but local availability and validation matter. [WHO HBV 2024 Guideline, diagnostic chapters; NVHCP Operational Guidelines, diagnostics and referral sections]
Differential Diagnosis
Do not label every jaundice syndrome as HBV. Acute hepatitis can arise from hepatitis A, C, D or E, Epstein-Barr virus, cytomegalovirus, drug-induced liver injury, alcohol-associated hepatitis, ischaemic injury, autoimmune hepatitis, biliary obstruction and metabolic disease. History, pattern of liver tests, pregnancy status, ultrasound and targeted serology help direct testing. Paracetamol toxicity, severe sepsis and ischaemic hepatitis can produce marked aminotransferase elevation and need urgent treatment pathways distinct from viral hepatitis.
In an HBsAg-positive person, distinguish acute infection, chronic infection, flare, reactivation, inactive infection and coincidental non-HBV liver disease. A single test cannot safely determine phase or treatment need. HBsAg persisting for six months establishes chronic infection in standard definitions; document dates rather than guessing chronicity. Raised ALT can reflect alcohol, fatty liver, medicines, HCV, HDV, HIV or immune-active HBV. Low or undetectable HBV DNA at one visit does not permanently exclude future activity.
Cirrhosis complications may present with ascites, variceal bleeding, encephalopathy, jaundice, renal dysfunction or liver mass. These are not explained by an uncomplicated carrier label. In India, acute hepatitis E and medicine-related liver injury are important alternatives in a patient with acute jaundice, while tuberculosis or other systemic infection can complicate liver tests. Test rather than infer, and involve hepatology or emergency services when liver failure is possible. [WHO HBV Fact Sheet, diagnosis limits; WHO HBV 2024 Guideline, monitoring and liver disease chapters]
Management
Acute uncomplicated hepatitis B is managed with rest as needed, adequate oral intake, antiemetic or symptom treatment where appropriate, avoidance of alcohol and potentially hepatotoxic medicines, and clinical follow-up. There is no routine specific antiviral treatment for every acute case. Admit or urgently refer when there is encephalopathy, INR prolongation, severe vomiting/dehydration, hypoglycaemia, rising bilirubin with clinical deterioration, sepsis or concern for acute liver failure. Explain transmission prevention and offer testing and vaccination to eligible contacts through local services.
For chronic HBV, establish linkage to a service able to assess fibrosis, viral load, ALT, coinfections, pregnancy and eligibility for antiviral therapy. WHO 2024 expanded and simplified treatment criteria, but the exact decision requires the full current algorithm; do not substitute an isolated ALT, a single DNA result or a generic online score. People with cirrhosis, significant fibrosis, active hepatitis, HIV coinfection or other qualifying features require timely specialist-led or trained decentralised care. Monitoring continues whether treatment is started or deferred.
Support liver health: avoid alcohol, review medicines and supplements, manage diabetes and obesity, vaccinate susceptible contacts, use condoms where appropriate and do not share razors, toothbrushes or injection equipment. Surveillance for hepatocellular carcinoma is risk-based and must follow a current local protocol; it is not eliminated by a normal one-time ultrasound. The WHO model supports decentralised task sharing, but referral capability, imaging and laboratory access vary across India. [WHO HBV 2024 Guideline, treatment and service delivery chapters; WHO Consolidated Handbook 2026, care continuum]
Prescribing Information
Tenofovir disoproxil fumarate and entecavir are WHO-described oral options for chronic HBV, selected after assessment of indication, renal function, bone risk, pregnancy, HIV status, prior antiviral exposure and local access. Most people who begin HBV treatment need long-term therapy, so adherence, refill continuity and monitoring are safety issues. Do not start, stop or substitute an antiviral based on a single laboratory result without a clinician experienced in chronic HBV. Stopping therapy can cause clinically significant flare.
Before prescribing, confirm the diagnosis and obtain baseline renal function, liver disease assessment and relevant HIV testing. In HIV coinfection, avoid functional HBV monotherapy that could compromise HIV treatment; coordinate with HIV services. Pregnancy-related antiviral prophylaxis and infant immunoprophylaxis require obstetric, paediatric and programme coordination, with the actual regimen taken from the current Indian protocol. Interferon, nucleos(t)ide analogues and rescue treatment have different indications and adverse-effect profiles; they are not interchangeable.
Acute viral hepatitis does not justify routine antibiotics, corticosteroids, herbal liver tonics or unregulated supplements. Review paracetamol intake and avoid alcohol. Dose adjustments and monitoring need particular care in renal impairment and decompensated liver disease. Indian formulations, reimbursement and availability vary: verify CDSCO product information, institutional formulary and NVHCP supply rules at the point of care. This guide does not provide a self-medication dose schedule. [WHO HBV Fact Sheet, Treatment; WHO HBV 2024 Guideline, antiviral therapy and monitoring chapters]
When to Refer
Send urgently to emergency care for altered mental status, asterixis, gastrointestinal bleeding, shock, severe jaundice with deterioration, rapidly increasing abdominal distension, severe vomiting, suspected sepsis, pregnancy with severe illness, or any concern for acute liver failure. A patient with possible liver failure needs serial observation, INR, glucose and specialist-capable management; outpatient serology alone is unsafe. Refer urgently for ascites, encephalopathy, variceal bleeding, severe thrombocytopenia, acute kidney injury or a liver mass.
Refer or link promptly to a hepatitis treatment centre for newly diagnosed chronic HBV, detectable HBV DNA requiring interpretation, persistent ALT elevation, fibrosis/cirrhosis, coinfection, pregnancy, planned immunosuppression, dialysis, transplant assessment, antiviral resistance concern or suspected hepatocellular carcinoma. Family screening, counselling and vaccination can start in primary care but do not replace staging. Refer children to paediatric services familiar with age-specific treatment and prevention decisions.
NVHCP operational guidance describes a network with testing at multiple levels and model or district treatment centres. This is a programme intent, not proof that every district has elastography, HBV DNA, liver imaging, antiviral stock or a hepatologist. Confirm the receiving service and arrange result transfer, transport and follow-up. Use local emergency, gastroenterology, medicine, obstetric and infectious-disease routes instead of quoting foreign referral time standards. [NVHCP Operational Guidelines, diagnosis and treatment-centre plan; WHO Consolidated Handbook 2026, decentralised service delivery]
Red Flags
Red flags for acute liver failure include confusion, drowsiness, asterixis, hypoglycaemia, rapidly worsening jaundice, bleeding tendency, persistent vomiting, severe abdominal pain, reduced urine output and clinical instability. These require emergency assessment even before the full viral panel returns. A person with chronic HBV who develops haematemesis, melaena, ascites, fever with ascites, new encephalopathy, jaundice, oedema, progressive weight loss, bone pain or a palpable mass may have decompensation, infection or malignancy.
Pregnancy needs urgent review when HBV is newly identified late, viral load is high, there is jaundice or liver dysfunction, or delivery planning is uncertain. The goal is to prevent mother-to-child transmission while maintaining maternal safety and infant follow-up; it is not to isolate or shame the mother. Infants born to a person with HBV need timely programme-coordinated immunoprophylaxis and post-vaccination follow-up as locally specified.
Reactivation risk is a red flag before, during and after chemotherapy, B-cell-depleting treatment, high-dose steroids, transplant-related immunosuppression or certain targeted therapies. Ensure HBV testing and specialist planning before immunosuppression rather than reacting after hepatitis develops. Contact or household members with jaundice, fever or acute illness need assessment but do not require panic or casual-contact restriction. [WHO HBV 2024 Guideline, prevention and reactivation-related care; WHO Consolidated Handbook 2026, prevention and linkage chapters]
Indian Clinical Context
India's National Viral Hepatitis Control Programme provides the appropriate jurisdictional anchor for public-sector hepatitis services. Its operational guidance targets prevention, testing, treatment and referral, including safe injection practice, blood safety, antenatal screening mechanisms, high-risk-group screening, rapid tests, viral-load capacity and treatment centres. The document dates from the programme rollout and should be read alongside current NVHCP technical guidance and state implementation notices; it does not guarantee identical access across facilities.
At an Ayushman Arogya Mandir or primary facility, identify danger signs, draw or arrange quality-assured tests, counsel on transmission and vaccination, and create a documented referral loop. A district hospital or medical college may offer more diagnostics and treatment, but availability of HBV DNA, elastography, ultrasound surveillance, HDV testing, oncology and paediatric hepatology can differ. Do not ask a patient to travel repeatedly without confirming the destination, test requirements and expected costs.
Indian practice must also address stigma, misinformation, self-medication, alcohol and metabolic liver disease, and missed follow-up after migration or work travel. WHO recommendations are evidence-informed global guidance, not Indian law or a substitute for NVHCP medicine eligibility. Explain uncertainty honestly: laboratory interpretation, fibrosis staging and treatment thresholds may change with updated national guidance, and an individual plan must be reviewed by the responsible clinical service. [NVHCP Operational Guidelines, programme objectives and service structure; WHO HBV 2024 Guideline, scope]
NMC Competency Mapping
The NMC Competency Based Medical Education Curriculum 2024 expects graduates to approach common infectious and hepatobiliary presentations through focused history, examination, basic investigation selection, prevention counselling, first-line safety measures and referral within scope. Hepatitis B should be taught as an integrated medicine, microbiology, pharmacology, obstetric and community-health problem. Rather than inventing an unverified single code, learners should use their institution's live competency table and logbook for the exact code.
Observable skills include assessing jaundice and encephalopathy, eliciting blood and sexual exposure sensitively, distinguishing acute danger from stable chronic disease, interpreting the purpose of HBsAg and HBV DNA testing, identifying liver-failure and cirrhosis red flags, counselling on vaccination and household safety, and arranging non-stigmatising referral. Learners should explain that casual contact does not transmit HBV and that a diagnosis does not define character, sexual behaviour or parenting.
Students must recognise limits: they do not independently stage fibrosis, decide lifelong antiviral eligibility, stop antiviral treatment, manage decompensated cirrhosis or authorise a chemotherapy plan. A simulated station can assess a pregnant person with a positive HBsAg, a worker after needlestick exposure and a patient with ascites. Marking should reward safety, consent, communication, documentation and linkage to care as well as recall of viral markers. [NMC CBME 2024, curriculum framework and assessment principles]
Key Exam Pearls for NEET PG
HBV is transmitted through blood and body fluids, perinatal exposure, sexual contact and unsafe injections; it is not spread by ordinary casual contact. Acute infection may be asymptomatic or icteric, while chronic infection can silently progress to cirrhosis and hepatocellular carcinoma. Laboratory confirmation is essential because clinical hepatitis cannot reliably distinguish HBV from other viral and non-viral causes. HBsAg is a key test, but full interpretation uses the clinical setting and other markers.
Acute liver failure clues are encephalopathy and coagulopathy in acute hepatitis; treat this as an emergency. Chronic HBV assessment integrates ALT, HBV DNA, fibrosis/cirrhosis, coinfections and pregnancy rather than a single marker. Tenofovir and entecavir are major chronic-treatment options, but treatment is long-term for many patients and should not be stopped casually. Remember reactivation risk before immunosuppression.
Prevention anchors are vaccination, including timely infant vaccination, screened blood, safe injections and testing/linkage for key populations. For Indian answers, name NVHCP as the service framework but avoid claiming identical viral-load or treatment access everywhere. A strong answer combines transmission prevention, confirmation, liver staging, treatment eligibility assessment, surveillance for complications and precise referral. [WHO HBV Fact Sheet, Prevention and Treatment; NVHCP Operational Guidelines, prevention and treatment sections]
Frequently Asked Questions
Can hepatitis B spread through sharing meals, hugging or ordinary classroom contact?
No. HBV is transmitted through blood or certain body-fluid exposure, including perinatal, sexual and sharps exposure. Casual contact, sharing food and hugging do not transmit it. Families should use sensible blood precautions, avoid sharing razors or toothbrushes, arrange testing and vaccination for eligible contacts, and avoid isolating or blaming the affected person.
Does a positive HBsAg result by itself show whether lifelong antiviral treatment is needed?
No. HBsAg establishes current infection but treatment decisions also require assessment of duration, ALT, HBV DNA, fibrosis or cirrhosis, coinfections, pregnancy, immunosuppression risk and current guideline criteria. A single marker or online chart cannot safely replace a treatment-centre evaluation. People with severe symptoms or signs of liver failure need urgent care.
Should a person with hepatitis B stop alcohol and herbal liver products?
Avoid alcohol because it can accelerate liver injury. Review all prescribed, over-the-counter, traditional and herbal products with the clinical team, because some can injure the liver or interact with treatment. Do not stop essential prescribed antivirals independently. Supportive diet and hydration are useful in acute illness, but no tonic cures chronic HBV.
What is important when hepatitis B is identified during pregnancy?
Prompt linkage to obstetric, paediatric and hepatitis services is important to assess maternal disease, viral replication and prevention of mother-to-child transmission. Delivery planning, maternal antiviral prophylaxis where indicated, infant immunoprophylaxis and follow-up should follow current Indian programme and specialist guidance. A positive test is not a reason for stigma, isolation or automatically avoiding breastfeeding without individual clinical advice.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic